Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lamictal IR Experience Impresses Advisory Committee, Not XR Trial Design

This article was originally published in The Pink Sheet Daily

Executive Summary

Committee members recommend Lamictal XR as a monotherapy for partial seizures, relying on the knowledge that the immediate-release version of the drug works for the indication.
Advertisement

Related Content

FDA Advisory Committee Waivers Reflect Recruitment Challenges
FDA Advisory Committee Waivers Reflect Recruitment Challenges
Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials
Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials
Lamictal XR Monotherapy: Will Ex-U.S. Data Invalidate Historical Comparison?
Lamictal XR Monotherapy: Will Ex-U.S. Data Invalidate Historical Comparison?

Topics

Advertisement
UsernamePublicRestriction

Register

PS071935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel